Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

HDAC3 Is Required for Pathognomonic Features of Langerhans Cell Histiocytes

Peter Dimitrion, Jugmohit Toor, James Ge, Qiyan Wang, Carl E Allen, Li Zhou, Qing-Sheng Mi

Blood (2023) 142 (Supplement 1): 676.

https://doi.org/10.1182/blood-2023-185195

Published: 2023

Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Blood (2023) 142 (Supplement 1): 869.

https://doi.org/10.1182/blood-2023-187740

Published: 2023

Journal Articles

Developing “Off-the-Shelf” CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia

Xu Beilei, Chao Zhang, Junxiao Gao, Zhu Li, Shengzhen Ding, Li Liu, Hang Zhang, Lulu Lyu, Li Zhou

Blood (2023) 142 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2023-173608

Published: 2023

Journal Articles

C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse

Li-Xue Yang, Cheng-Tao Zhang, Meng-Ying Yang, Xue-Hong Zhang, Hong-Chen Liu, Chen-Hui Luo, Yue Jiang, Zhang-Man Wang, Zhong-Yin Yang, Zhao-Peng Shi, Yi-Ci Yang, Ruo-Qu Wei, Li Zhou, Jun Mi, Ai-Wu Zhou, Zhi-Rong Yao, Li Xia, Jin-Song Yan, Ying Lu

Blood (2023) 141 (7): 766–786.

https://doi.org/10.1182/blood.2022017046

Published: 2023

Includes: Supplemental data

Journal Articles

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Stephane De Botton, Thomas Cluzeau, MDPhD, Carlos Enrique Vigil, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Jane L. Liesveld, MD, Pierre Fenaux, MD PhD, Thorsten Braun, MD PhD, Anne Banos, MD, Michael R. Savona, MD, Don Park, MD, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Eytan M. Stein, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134600

Published: 2020

Journal Articles

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Eytan M. Stein, MD, Stephane De Botton, Thomas Cluzeau, MDPhD, Arnaud Pigneux, MD PhD, Jane L. Liesveld, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Thorsten Braun, MD PhD, Dale L. Bixby, MD, Gail J. Roboz, MD, Delphine Lebon, MD, Mael Heiblig, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Pierre Peterlin, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-134602

Published: 2020

Journal Articles

Selection of RARA-Positive Newly Diagnosed Unfit AML Patients with Elevated RARA Gene Expression Enriches for Features Associated with Primary Resistance to Venetoclax and Clinical Response to SY-1425, a Potent and Selective RARα Agonist, Plus Azacitidine

Christopher Fiore, PhD, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Kate Madigan, MD, Matthew Eaton, PhD, Graeme Hodgson, PhD, David A. Roth, MD, Qing Kang-Fortner, PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137323

Published: 2020

Journal Articles

Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China

Li Zhou, Bingcheng Liu, Jianda Hu, PhD, Jianhua Qu, Ming Hou, MD, Hui Sun, Jie Jin, MD PhD, Zhixiang Shen

Blood (2019) 134 (Supplement_1): 5914.

https://doi.org/10.1182/blood-2019-126546

Published: 2019

Journal Articles

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Andres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, Michael S. Wertheim, William J. Edenfield, Paolo Caimi, Martin Gutierrez, Luke Akard, Carolina Escobar, Justin Call, Daniel Persky, Swaminathan Iyer, Douglas J. DeMarini, Li Zhou, Xuejun Chen, Fitzroy Dawkins, Tycel J. Phillips

Blood (2019) 133 (16): 1742–1752.

https://doi.org/10.1182/blood-2018-08-867499

Published: 2019

Includes: Supplemental data

Journal Articles

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma

Tycel J. Phillips, Andres Forero-Torres, Taimur Sher, Catherine S. Diefenbach, Patrick Johnston, Moshe Talpaz, Jennifer Pulini, Li Zhou, Peggy Scherle, Xuejun Chen, Paul M. Barr

Blood (2018) 132 (3): 293–306.

https://doi.org/10.1182/blood-2017-10-812701

Published: 2018

Includes: Supplemental data

Journal Articles

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Andres Forero-Torres, MD, Rod Ramchandren, MD, Abdulraheem Yacoub, MD, Michael S. Wertheim, MD, William J. Edenfield, MD, Paolo Caimi, MD, Martin Gutierrez, MD, Luke Akard, MD, Carolina Escobar, MD, Justin Call, MD, Daniel Persky, MD, Swami P. Iyer, MD, Douglas J. DeMarini, PhD, Li Zhou, PhD, Swamy Yeleswaram, PhD, Tycel J. Phillips, MD

Blood (2017) 130 (Supplement 1): 410.

https://doi.org/10.1182/blood.V130.Suppl_1.410.410

Published: 2017

Journal Articles

Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA

Florian Scherer, MD, David M. Kurtz, MD, Aaron M Newman, PhD, Alexander Craig, MPhil, Henning Stehr, PhD, Li Zhou, Cynthia Glover, Holbrook Kohrt, MD, Ronald Levy, MD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2016) 128 (22): 1752.

https://doi.org/10.1182/blood.V128.22.1752.1752

Published: 2016

Journal Articles

Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma

Blood (2016) 128 (22): 1089.

https://doi.org/10.1182/blood.V128.22.1089.1089

Published: 2016

Journal Articles

Ginkgo Biloba Extract Blunts the Prothrombotic Effect of Thalidomide on Human Umbilical Endothelial Cells

Rui-Nan Lu, MD, PhD, Ling Wang, MS., Li Zhou, MS., Jianyong Li, MD PhD, Hua Lu, MD

Blood (2016) 128 (22): 5009.

https://doi.org/10.1182/blood.V128.22.5009.5009

Published: 2016

Journal Articles

Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations

Max Jan, MD PhD, Florian Scherer, MD, David M. Kurtz, MD, Aaron M Newman, PhD, Henning Stehr, PhD, Chih Long Liu, PhD, Li Zhou, Cynthia Glover, Ranjana H Advani, MD, Lauren S Maeda, MD, Neel K. Gupta, MD, Ronald Levy, MD, Christian A. Kunder, MD PhD, Isidro Sánchez-García, MD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2016) 128 (22): 4107.

https://doi.org/10.1182/blood.V128.22.4107.4107

Published: 2016

Journal Articles

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Tycel Phillips, MD, Rod Ramchandren, MD, Michael S Wertheim, MD, Martin E Gutierrez, MD, William J Edenfield, MD, Fitzroy Dawkins, MD, Doug J DeMarini, Li Zhou, PhD, Swamy Yeleswaram, PhD, Robert C Newton, PhD, Xuejun Chen, PhD, Andres Forero-Torres, MD

Blood (2016) 128 (22): 4195.

https://doi.org/10.1182/blood.V128.22.4195.4195

Published: 2016

Journal Articles

Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia

Thomas B. Alexander, MD MPH, Zhaohui Gu, PhD, John K Choi, MD, Mignon L. Loh, MD, John Horan, MD MPH, Barbara Buldini, MD, Giuseppe Basso, Sarah Elitzur, MD, C. Michel Zwaan, MD PhD, Valerie de Haas, MD PhD, Allen Eng Juh Yeoh, MD, Dirk Reinhardt, MD PhD, Daisuke Tomizawa, MD, PhD, Tim Lammens, Barbara De Moerloose, MD, Li Zhou, PhD, Hiroki Hori, MD PhD, Anthony V. Moorman, PhD, Andrew S. Moore, MBBS FRACP PhD, Ondrej Hrusak, MD PhD, Soheil Meshinchi, MD PhD, Etan Orgel, MD MS, Meenakshi Devidas, PhD, Stephen P. Hunger, MD, Jamie M Guidry Auvil, Malcolm A. Smith, MD PhD, Tanja M. Davidsen, PhD, Leandro C. Hermida, Patee Gesuwan, Marco A. Marra, PhD, Yussanne Ma, PhD, Andrew J. Mungall, Richard Moore, PhD, Daniela S. Gerhard, PhD, Xueyuan Cao, Lei Shi, PhD, Stanley Pounds, PhD, Hiroto Inaba, MD PhD, Charles Mullighan, MBBS, MSc, MD

Blood (2016) 128 (22): 454.

https://doi.org/10.1182/blood.V128.22.454.454

Published: 2016

Journal Articles

Noninvasive Detection of BCL2 , BCL6 , and MYC Translocations in Diffuse Large B-Cell Lymphoma

Blood (2016) 128 (22): 2930.

https://doi.org/10.1182/blood.V128.22.2930.2930

Published: 2016

Journal Articles

Age-Adjusted Telomere Length May Predict Treatment-Related Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation

Pasquale M Barbaro, MBBS FRACP FRCPA, Peter J. Shaw, MBBS, FRACP, MA, MRCP, Melissa Gabriel, MBBS, FRACP, Steven Keogh, MBBS (Hons), FRACP, Li Zhou, PhD, Daniel Catchpole, PhDFFSc(RCPA), Loretta Lau, MBBS, MMed, PhD FRACP, Rebecca Dagg, BSc (Hons), Hilda A Pickett, BSc (Hons) PhD, Roger R Reddel, BSc (MD MBBS PhDFRACP FAA

Blood (2015) 126 (23): 5445.

https://doi.org/10.1182/blood.V126.23.5445.5445

Published: 2015

NARROW

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

HDAC3 Is Required for Pathognomonic Features of Langerhans Cell Histiocytes

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Developing “Off-the-Shelf” CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia

C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Selection of RARA-Positive Newly Diagnosed Unfit AML Patients with Elevated RARA Gene Expression Enriches for Features Associated with Primary Resistance to Venetoclax and Clinical Response to SY-1425, a Potent and Selective RARα Agonist, Plus Azacitidine

Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA

Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma

Ginkgo Biloba Extract Blunts the Prothrombotic Effect of Thalidomide on Human Umbilical Endothelial Cells

Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia

Noninvasive Detection of BCL2 , BCL6 , and MYC Translocations in Diffuse Large B-Cell Lymphoma

Age-Adjusted Telomere Length May Predict Treatment-Related Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only